FT836
Acute Myeloid Leukemia (AML) & Solid Tumors
Phase 1Active
Key Facts
Indication
Acute Myeloid Leukemia (AML) & Solid Tumors
Phase
Phase 1
Status
Active
Company
About Fate Therapeutics
Fate Therapeutics is dedicated to transforming patient lives with autoimmune diseases and cancer through its proprietary iPSC platform, which generates 'off-the-shelf' cell therapies. The company's mission is to make cell therapy delivery routine and accessible by developing multiplexed-engineered cell product candidates that incorporate novel synthetic controls of cell function. Its pipeline includes several clinical-stage candidates, such as FT819, FT825, FT836, FT839, and FT522, targeting both oncology and autoimmune indications. Fate operates as a public company, leveraging strategic collaborations to advance its science and clinical development.
View full company profile